Restoring Microvessels,
Redefining Health

Curacle develops first-in-class therapies restoring microvascular function
in aging
and chronic diseases.

OUR TECHNOLOGY

with SOLVADYS^® Platform

with EAGLES^® Platform

Rivasterat (CU06)

Rivasterat (CU06)

The first oral Endothelial Dysfunction Blocker.
CU01

CU01

A dual-function therapy targeting NRF2 activation and TGF-β inhibition.
MT-101

MT-101

The first fully humanized Tie2 agonist antibody.
MT-103

MT-103

The first bispecific antibody with a real Tie2 agonist function.
MT-105

MT-105

Triple Antibody for Inflammatory Bowel Disease
MT-201

MT-201

A non-bleeding anti-thrombotic antibody targeting PD-X.
MT-202

MT-202

A dual-mechanism therapy combining PD-X inhibition and Tie2 agonism.
CU71

CU71

Next-generation Neurovascular Stabilizer.
CP01-R01

CP01-R01

First-in-class oral candidate for companion animal CKD.

Memento Medicines Launches with $93 Million Series A Financing to advance Tie2 Agonist and VEGF Inhibitor Bispecific Antibody Therapy for Retinal Diseases

https://www.globenewswire.com/news-release/2026/06/18/3314508/0/en/memento-medicines-launches-with-93-million-series-a-financing-to-advance-tie2-agoni...
Curacle Receives Upfront Payment from Global Licensing Deal for MT-103

Curacle Co., Ltd. (KOSDAQ:
365270), a biopharmaceutical company focused on therapies for vascular
dysfunction, announced on 6/5 through a public dis...
Curacle Shares Rise for Second Straight Day on Up to 1.6 Trillion Won Licensing Deal

https://pharm.edaily.co.kr/News/Read?newsId=03073366645448264&mediaCodeNo=257